Who is sponsoring NCT05030246?

NCT05030246 is sponsored by Peking University.

What drugs are being tested in NCT05030246?

Interventions in NCT05030246: Surufatinib/Toripalimab.

Is NCT05030246 still recruiting?

NCT05030246 is currently status unknown. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT05030246

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Status unknown Phase 2 Last updated 1 September 2021

What this trial tests

Phase 2 trial testing Surufatinib/Toripalimab in Refractory Metastatic Digestive System Carcinoma in 72 participants. Status unknown.

Timeline

14 July 2021

Primary endpoint
30 April 2023

30 July 2023

Quick facts

Lead sponsor	Peking University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	14 July 2021
Primary completion	30 April 2023
Estimated completion	30 July 2023
Sites	1 location across China

Drugs / interventions tested

Surufatinib/Toripalimab — full drug profile →

Conditions studied

Refractory Metastatic Digestive System Carcinoma — all drugs for Refractory Metastatic Digestive System Carcinoma →
Primary Peritoneal Cancer — all drugs for Primary Peritoneal Cancer →

Sponsor

Peking University

Who can join

18 and older, any sex, with Refractory Metastatic Digestive System Carcinoma or Primary Peritoneal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Surufatinib combined with Toripalimab in patients with peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells.
Luo S, Yang G, Ye P, Cao N, et al · · 2022 · cited 38× · PMID 35740975 · DOI 10.3390/biom12060850
Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
Ornella MSC, Badrinath N, Kim KA, Kim JH, et al · · 2023 · cited 24× · PMID 37190310 · DOI 10.3390/cancers15082383
Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749

Verify or expand the search:

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05030246 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05030246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing